Creating Medicines That Impact Global Health


Agile Life-Sciences (“ALS”) mission is to develop best-in-class drugs using Biopolymer-encaspulated D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP) platform for the treatment of Atherosclerosis, Type-II Diabetes, Cerebrovascular Disease, Alzheimer’s and other indications.

The Problem


Globally the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. In 2016 an estimated 1.6 million deaths were directly caused by diabetes, the 7th leading cause of death in 2016.

Cardiovascular (CV) Disease

CV was the leading cause of death in the United States in 2016, accounting for more than 900,000 deaths. Atherosclerosis is implicated as the underlying cause of around 50% of all deaths in westernized society and is a primary cause of heart attacks, strokes and peripheral artery disease.

Alzheimer’s Disease

There are more than 5 million people with Alzheimer’s disease in the U.S. and 35million worldwide. These numbers are expected to skyrocket to a projected 13.8 million and 115 million respectively by mid-century. In the United States, 10,000 baby boomers turn 65 each day, and the 85-plus population is one of our fastest growing segments. While Alzheimer’s costs $259 billion in the United States alone, this number will increase to $1.2 trillion by 2050 unless we find a way to prevent, treat or delay the disease.